$234.84
0.55%
Downside
Day's Volatility :2.81%
Upside
2.28%
39.54%
Downside
52 Weeks Volatility :46.16%
Upside
10.95%
Period | Alnylam Pharmaceuticals, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 65.99% | 6.5% | 0.0% |
6 Months | 32.44% | 7.1% | 0.0% |
1 Year | 22.03% | 9.8% | 0.0% |
3 Years | 33.56% | 14.2% | -20.2% |
Market Capitalization | 29.9B |
Book Value | - $1.73 |
Earnings Per Share (EPS) | -2.65 |
PEG Ratio | -0.49 |
Wall Street Target Price | 261.15 |
Profit Margin | -16.58% |
Operating Margin TTM | -8.79% |
Return On Assets TTM | -3.05% |
Return On Equity TTM | -1500.66% |
Revenue TTM | 2.0B |
Revenue Per Share TTM | 15.97 |
Quarterly Revenue Growth YOY | 54.800000000000004% |
Gross Profit TTM | 868.6M |
EBITDA | -122.3M |
Diluted Eps TTM | -2.65 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.55 |
EPS Estimate Next Year | -1.62 |
EPS Estimate Current Quarter | -1.18 |
EPS Estimate Next Quarter | -1.04 |
What analysts predicted
Upside of 11.2%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 74.9M | ↓ 16.69% |
Net Income | -761.5M | ↑ 55.13% |
Net Profit Margin | -1.0K% | ↓ 470.63% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 219.8M | ↑ 193.36% |
Net Income | -886.1M | ↑ 16.37% |
Net Profit Margin | -403.24% | ↑ 613.34% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 492.9M | ↑ 124.28% |
Net Income | -858.3M | ↓ 3.14% |
Net Profit Margin | -174.15% | ↑ 229.09% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 844.3M | ↑ 71.31% |
Net Income | -852.8M | ↓ 0.64% |
Net Profit Margin | -101.01% | ↑ 73.14% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 1.0B | ↑ 22.88% |
Net Income | -1.1B | ↑ 32.64% |
Net Profit Margin | -109.04% | ↓ 8.03% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 1.8B | ↑ 76.23% |
Net Income | -440.2M | ↓ 61.08% |
Net Profit Margin | -24.08% | ↑ 84.96% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 335.0M | ↑ 26.76% |
Net Income | -207.5M | ↓ 48.88% |
Net Profit Margin | -61.93% | ↑ 91.65% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 319.3M | ↓ 4.7% |
Net Income | -174.1M | ↓ 16.09% |
Net Profit Margin | -54.53% | ↑ 7.4% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 318.8M | ↓ 0.17% |
Net Income | -276.0M | ↑ 58.54% |
Net Profit Margin | -86.59% | ↓ 32.06% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 750.5M | ↑ 135.46% |
Net Income | 147.8M | ↓ 153.53% |
Net Profit Margin | 19.69% | ↑ 106.28% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 439.7M | ↓ 41.41% |
Net Income | -137.9M | ↓ 193.31% |
Net Profit Margin | -31.35% | ↓ 51.04% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 494.3M | ↑ 12.42% |
Net Income | -65.9M | ↓ 52.18% |
Net Profit Margin | -13.34% | ↑ 18.01% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 1.6B | ↓ 21.05% |
Total Liabilities | 272.8M | ↑ 19.51% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 2.4B | ↑ 52.09% |
Total Liabilities | 956.4M | ↑ 250.55% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 3.4B | ↑ 42.25% |
Total Liabilities | 2.4B | ↑ 149.97% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 3.6B | ↑ 6.93% |
Total Liabilities | 3.1B | ↑ 27.78% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 3.5B | ↓ 2.66% |
Total Liabilities | 3.7B | ↑ 21.26% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 3.8B | ↑ 7.99% |
Total Liabilities | 4.1B | ↑ 9.34% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 3.5B | ↑ 0.31% |
Total Liabilities | 3.7B | ↑ 2.82% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.4B | ↓ 4.35% |
Total Liabilities | 3.7B | ↓ 1.44% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.4B | ↑ 0.31% |
Total Liabilities | 3.8B | ↑ 4.36% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.8B | ↑ 12.83% |
Total Liabilities | 4.0B | ↑ 5.1% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.8B | ↓ 0.24% |
Total Liabilities | 4.1B | ↑ 1.14% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 3.8B | ↓ 0.14% |
Total Liabilities | 4.0B | ↓ 0.17% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -562.6M | ↑ 46.98% |
Investing Cash Flow | 272.9M | ↓ 194.0% |
Financing Cash Flow | 65.5M | ↓ 94.18% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -278.4M | ↓ 50.51% |
Investing Cash Flow | -417.7M | ↓ 253.03% |
Financing Cash Flow | 823.2M | ↑ 1157.35% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -615.0M | ↑ 120.87% |
Investing Cash Flow | -435.5M | ↑ 4.27% |
Financing Cash Flow | 995.0M | ↑ 20.87% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -641.7M | ↑ 4.35% |
Investing Cash Flow | -273.3M | ↓ 37.25% |
Financing Cash Flow | 1.2B | ↑ 25.34% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -541.3M | ↓ 15.65% |
Investing Cash Flow | 169.4M | ↓ 161.97% |
Financing Cash Flow | 425.8M | ↓ 65.86% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -132.0M | ↑ 14.48% |
Investing Cash Flow | -139.9M | ↓ 144.57% |
Financing Cash Flow | 63.4M | ↓ 78.64% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -166.5M | ↑ 26.14% |
Investing Cash Flow | -76.2M | ↓ 45.52% |
Financing Cash Flow | 46.4M | ↓ 26.9% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -59.0M | ↓ 64.57% |
Investing Cash Flow | -8.7M | ↓ 88.57% |
Financing Cash Flow | 53.4M | ↑ 15.15% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 359.4M | ↓ 709.32% |
Investing Cash Flow | -10.8M | ↑ 23.54% |
Financing Cash Flow | 33.1M | ↓ 37.94% |
Sell
Neutral
Buy
Alnylam Pharmaceuticals, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Alnylam Pharmaceuticals, Inc. | -2.97% | 32.44% | 22.03% | 33.56% | 211.52% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -3.55 | -15.01 | -0.03 | NA | -1.73 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Alnylam Pharmaceuticals, Inc. | Buy | $29.9B | 211.52% | NA | -16.58% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Alnylam Pharmaceuticals, Inc.
Revenue is up for the last 2 quarters, 439.71M → 494.33M (in $), with an average increase of 11.1% per quarter
Netprofit is up for the last 2 quarters, -137.87M → -65.93M (in $), with an average increase of 109.1% per quarter
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 39.6%
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 152.9%
Capital World Investors
Vanguard Group Inc
FMR Inc
BlackRock Inc
Wellington Management Company LLP
Baillie Gifford & Co Limited.
Alnylam Pharmaceuticals, Inc.’s price-to-earnings ratio stands at None
Read Morealnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.
Organization | Alnylam Pharmaceuticals, Inc. |
Employees | 2100 |
CEO | Dr. Yvonne L. Greenstreet M.B.A., MBChB |
Industry | Health Technology |